المؤلفون: Glimelius, B., Sorbye, H., Balteskard, L., Bystrom, P., Pfeiffer, P., Tveit, K., Heikkila, R., Keldsen, N., Albertsson, Maria, Starkhammar, H., Garmo, H., Berglund, A.

المصدر: Annals of Oncology. 19(5):909-914

مصطلحات موضوعية: chemotherapy, irinotecan, 5-fluorouracil, randomized trial, colorectal cancer, Medicin och hälsovetenskap, Klinisk medicin, Cancer och onkologi, Medical and Health Sciences, Clinical Medicine, Cancer and Oncology

الوصف: Background: To compare irinotecan with the Nordic 5- fluorouracil (5- FU) and folinic acid (FA) bolus schedule [ irinotecan 180 mg/m(2) on day 1, 5- FU 500 mg/m(2) and FA 60 mg/m(2) on day 1 and 2 (FLIRI)] or the Lv5FU2 schedule [ irinotecan 180 mg/m(2) on day 1, FA 200 mg/m(2), 5- FU bolus 400 mg/m(2) and infused 5- FU 600 mg/m(2) on day 1 and 2 (Lv5FU2- IRI)] due to uncertainties about how to administrate 5- FU with irinotecan. Patients and methods: Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2- IRI. Primary end point was progression- free survival (PFS). Results: Patient characteristics were well balanced. PFS did not differ between groups (median 9 months, P = 0.22). Overall survival (OS) was also similar (median 19 months, P = 0.9). Fewer objective responses were seen in the FLIRI group (35% versus 49%, P = 0.001) but the metastatic resection rate did not differ (4% versus 6%, P = 0.3). Grade 3/4 neutropenia (11% versus 5%, P = 0.01) and grade 2 alopecia (18% versus 9%, P = 0.002) were more common in the FLIRI group. The 60- day mortality was 2.4% versus 2.1%. Conclusions: Irinotecan with the bolus Nordic schedule (FLIRI) is a convenient treatment with PFS and OS comparable to irinotecan with the Lv5FU2 schedule. Neutropenia and alopecia are more prevalent, but both regimens are equally well tolerated.

الوصول الحر: https://lup.lub.lu.se/record/1204941Test
http://dx.doi.org/10.1093/annonc/mdm588Test

المؤلفون: Glimelius, B, Sorbye, H, Balteskard, L, Bystrom, P, Pfeiffer, P, Tveit, K, Heikkila, R, Keldsen, N, Albertsson, M, Starkhammar, H, Garmo, H, Berglund, A

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology. 19(5):909-914

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:116968774Test

المؤلفون: Tveit, K, Guren, T, Glimelius, B, Pfeiffer, P, Sorbye, H, Pyrhonen, S, Kure, E, Ikdahl, T, Skovlund, E, Christoffersen, T

المصدر: ANNALS OF ONCOLOGY. 21:9-9

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:121981132Test

المؤلفون: Glimelius, B, Sorbye, H, Balteskard, L, Bystrom, P, Pfeiffer, P, Tveit, K, Heikkila, R, Keldsen, N, Albertsson, M, Starkhammar, H, Berglund, A

المصدر: EJC SUPPLEMENTS. 3(2):167-167

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:115486532Test